SC
ETRM

Sophrosyne Capital’s EnteroMedics Inc. ETRM Stock Holding History

Sophrosyne Capital’s Portfolio ETRM Stock Details ETRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-286
Closed -$468K – 79
2014
Q2 		$468K Buy
+286
New +$535K 0.48% 39

Other funds holding ETRM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Sophrosyne Capital's ETRM Position: Q3 2014 in Review

Sophrosyne Capital sold out of EnteroMedics Inc. (ETRM) in Q3 2014, closing a stake of 286 shares — an estimated $468K sold.

Sophrosyne Capital first reported a position in ETRM in Q2 2014 and held it in 1 quarter. The position peaked at $468K in Q2 2014. 49 funds tracked by Wall St. Rank hold ETRM as of Q3 2014.

  • Sophrosyne Capital reported no remaining EnteroMedics Inc. position as of Q3 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 286 EnteroMedics Inc. shares in Q3 2014, an estimated $468K.
  • Sophrosyne Capital first reported a position in EnteroMedics Inc. in Q2 2014 and held it in 1 quarter.
  • Sophrosyne Capital's EnteroMedics Inc. position peaked at $468K in Q2 2014.
  • 49 funds tracked by Wall St. Rank held EnteroMedics Inc. as of Q3 2014.

Based on Sophrosyne Capital's 13F filing for Q3 2014, filed 14 Nov 2014.